Immunoglobulin G4-related sclerosing disease

This phase 3 study tests whether the oral drug rilzabrutinib can prevent disease flares in adults with active IgG4-related disease, a rare condition causing swelling and organ damage. About 124 participants will receive either rilzabrutinib or a placebo for 52 weeks, alongside st…

This early-stage trial tests a new therapy called FKC289, which uses a patient's own immune cells engineered to target two proteins (BCMA and CD19) on cells that drive autoimmune attacks. The goal is to see if it is safe and can help control kidney diseases like lupus nephritis a…

This phase 2 trial is testing whether filgotinib, a drug already used for arthritis, can help people with three rare immune diseases: Behçet's disease, myositis, and IgG4-related disease. The goal is to see if it can control disease activity and reduce the need for long-term ster…

This study tests two treatment plans for people with IgG4-related disease affecting superficial organs like glands or skin. One group gets prednisone plus iguratimod, the other gets prednisone plus leflunomide. Over 12 months, researchers will track how many patients have a relap…

This early-stage trial tests a new treatment called ACE1831 for people with IgG4-related disease, a rare condition where the immune system attacks the body, causing swelling and organ damage. ACE1831 is made from healthy donor cells and given as an infusion. The study will check …

This study tests whether adding lenalidomide to standard steroid treatment can better control active IgG4-related disease (IgG4-RD), a rare condition that causes swelling and damage in organs. About 198 adults will receive either lenalidomide plus prednisone or prednisone alone f…

This Phase 2 trial tests a personalized cell therapy called anti-BCMA-CD19 CAR-T cells in 9 adults with IgG4-related disease that hasn't responded to standard treatments. Participants receive an infusion of their own modified immune cells after a short course of chemotherapy. The…

This study is testing a new scoring system called OC26 to help doctors more accurately diagnose autoimmune pancreatitis, a condition where the immune system attacks the pancreas. Researchers will review medical data from 82 adults suspected of having the disease. If the OC26 crit…

This study is testing a new radioactive tracer called [18F]AlF-FAPI-74 for PET/CT scans to see if it can find inflammation better than the current standard tracer. The trial will involve 140 people with fever of unknown origin, IgG4-related disease, or axial spondylarthritis. Res…

This study is creating a large database to collect information on people with rare diseases like amyloidosis, sarcoidosis, and Gaucher disease. Researchers will track patients' health over time, including their symptoms, treatments, and outcomes. The goal is to improve diagnosis …